- Home
- IINN vs PHGE Comparison
IINN vs PHGE Comparison
Compare IINN & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- PHGE
- Stock Information
- Founded
- IINN 2018
- PHGE 2015
- Country
- IINN Israel
- PHGE Israel
- Employees
- IINN N/A
- PHGE N/A
- Industry
- IINN Medical/Dental Instruments
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- PHGE Health Care
- Exchange
- IINN Nasdaq
- PHGE Nasdaq
- Market Cap
- IINN 13.7M
- PHGE 11.0M
- IPO Year
- IINN 2021
- PHGE N/A
- Fundamental
- Price
- IINN $1.08
- PHGE $0.44
- Analyst Decision
- IINN Strong Buy
- PHGE Strong Buy
- Analyst Count
- IINN 1
- PHGE 1
- Target Price
- IINN $2.00
- PHGE $15.00
- AVG Volume (30 Days)
- IINN 994.1K
- PHGE 284.6K
- Earning Date
- IINN 08-14-2025
- PHGE 08-13-2025
- Dividend Yield
- IINN N/A
- PHGE N/A
- EPS Growth
- IINN N/A
- PHGE N/A
- EPS
- IINN N/A
- PHGE N/A
- Revenue
- IINN N/A
- PHGE N/A
- Revenue This Year
- IINN N/A
- PHGE N/A
- Revenue Next Year
- IINN N/A
- PHGE N/A
- P/E Ratio
- IINN N/A
- PHGE N/A
- Revenue Growth
- IINN N/A
- PHGE N/A
- 52 Week Low
- IINN $0.40
- PHGE $0.34
- 52 Week High
- IINN $1.60
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- IINN 74.93
- PHGE 43.34
- Support Level
- IINN $0.77
- PHGE $0.43
- Resistance Level
- IINN $0.89
- PHGE $0.48
- Average True Range (ATR)
- IINN 0.08
- PHGE 0.05
- MACD
- IINN 0.02
- PHGE 0.00
- Stochastic Oscillator
- IINN 86.67
- PHGE 58.82
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).